- Esperion ( NASDAQ: ESPR ) expects fourth quarter 2022 U.S. net product revenue to be between $14.4M-$15.1M; full year growth between 38% and 40% Y/Y.
- The company also said that based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals .
- As of December 31, 2022, cash and investment securities available-for-sale totaled ~$167M.
- The new partnership with RFK Racing to increase brand awareness and drive accelerated growth .
- Based on the robustness of the CLEAR Outcomes data, the company believes it would be entitled to receive milestone payments from collaborative partners upon inclusion of cardiovascular risk reduction data in the U.S. and European labels.
- Shares of ESPR are down 2.06% after-hours.
For further details see:
Esperion sees preliminary Q4 U.S. net product revenue $14.4M-$15.1M